Blis Technologies Limited Analysis

Overview

Blis is an NZX-listed manufacturer of advanced probiotic strains that enable the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support and teeth and gum health. Combining innovation with evidence-based research has enabled the company to develop a range of products containing two strains of probiotic bacteria - BLIS K12 TM and BLIS M18 TM. Both of these strains occur naturally in the oral cavity however, only around 2% of the population have these healthy bacteria at levels high enough to be effective.

BLIS products have received regulatory approvals for sale throughout New Zealand, Australia, Asia, Europe and the USA. Brand names include ThroatGuard PRO, DailyDefence, TravelProtect, HoneyBlis, FreshBreath and ToothGuard.

Blis probiotics have a significant body of evidence which is constantly growing as more clinical trials are completed. Blis probiotics have been included in more than 40 clinical trials to date.

The company's origins lie in research undertaken by Professor Emeritus John Tagg of the Microbiology Department at the University of Otago in New Zealand who found that Salivaricin B, a substance which acts as a natural antibiotic, controls streptococcal throat infections. Blis Technologies commenced business in August 2000 when it acquired the University's collection of several thousand bacteriocin-producing organisms. It listed on NZX in 2001.

Performance

The following information was extracted from BLIS Technologies Limited's market update, released on 21 February 2025:

Revenue Growth and Profitable Third Quarter

For the third quarter ending 31 December 2024, Blis Technologies Limited (BLIS) delivered revenue of $3.2m, being growth of 4% on the same period last year and a positive EBITDA result of $0.3m (unaudited).

The nine months to 31 December 2024 saw revenue growth of 17% on the same period last year. This revenue growth has predominantly come from a $0.9m (34%) increase in B2C revenue across the Daigou, Amazon and webstore channels, with B2B channel delivering growth of $0.5m (8%) growth.

“While the B2B channel remains the core pillar of the BLIS business, our B2C focus has been on increasing profitability in existing channels. BLIS’ will continue to focus on winning in the right markets with key business partners. This will allow us to leverage the increased consumer awareness of the importance of maintaining a healthy oral microbiome for overall good health and wellbeing and is driving them to seek out BLIS’ clinically proven probiotic solutions.” said Scott Johnson, CEO.